文献速递主动脉疾病

ACE2、COVID-19与腹主动脉瘤

Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2021-02-15

本文综述ACE2表达及ACE2-血管紧张素1-7-Mas受体轴活动在腹主动脉瘤(AAA)发病中的作用,以识别COVID-19对AAA疾病的潜在影响。所有血管结构细胞表达ACE2,吸烟、糖尿病、COPD、狼疮、某些恶性肿瘤和病毒感染促进ACE2表达,且反应幅度因性别和年龄而异。SARS-CoV-2可能通过多种机制理论性影响AAA疾病,需进一步研究和临床随访确定COVID-19大流行对AAA患病率、进展和致死率的影响。

要点

  • 所有血管结构细胞表达ACE2,吸烟、糖尿病等促进其表达。
  • ACE2激活或血管紧张素1-7治疗可减轻实验性AAA进展。
  • COVID-19可能通过多种机制理论性影响AAA疾病。

核心结论

  • COVID-19可能通过多种SARS-CoV-2诱导的机制理论性影响AAA疾病。
  • 需进一步研究和临床随访确定COVID-19大流行对AAA患病率、进展和致死率的影响。

研究设计与样本

  • 在PubMed和National Library of Medicine进行综合文献检索,关键词包括COVID-19、SARS-CoV-2、AAA、ACE2、ACE或AT1受体抑制剂、血管紧张素1-7、Mas受体、年龄、性别、呼吸系统疾病、糖尿病和自身免疫疾病。
  • 识别并综述COVID-19和AAA的流行病学和发病机制的关键出版物。

主要发现

  • 所有血管结构细胞,包括内皮和平滑肌细胞、成纤维细胞和周细胞,表达ACE2。
  • 吸烟、糖尿病、慢性阻塞性肺疾病、狼疮、某些类型的恶性肿瘤和病毒感染促进ACE2表达和活性,反应幅度因性别和年龄而异。
  • AT1受体遗传缺陷或药理学ACE或AT1抑制也增加ACE2及其催化产物血管紧张素1-7。
  • ACE2或Mas受体的遗传消融或药理学抑制增强实验性AAA的进展,而ACE2激活或血管紧张素1-7治疗减弱其进展。
  • SARS-CoV-2对AAA发病机制的潜在影响包括:ACE2-血管紧张素1-7-Mas激活减少导致ACE-血管紧张素II-AT1受体活性增强;病毒刺突蛋白刺激ACE2阴性髓系细胞或表达ACE2的血管结构细胞产生促动脉瘤介质增加;病毒靶向的非血管、非白细胞ACE2表达细胞通过配体识别其同源白细胞受体增强局部或全身交叉对话;严重COVID-19疾病期间的低氧血症和全身炎症张力增加。

局限性

  • COVID-19对AAA疾病的影响是理论性的,需进一步研究和临床随访确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the etiologic agent of the current, world-wide coronavirus disease 2019 (COVID-19) pandemic. Angiotensin-converting enzyme 2 (ACE2) is the SARS-CoV-2 host entry receptor for cellular inoculation and target organ injury. We reviewed ACE2 expression and the role of ACE2-angiotensin 1-7-Mas receptor axis activity in abdominal aortic aneurysm (AAA) pathogenesis to identify potential COVID-19 influences on AAA disease pathogenesis. METHODS: A comprehensive literature search was performed on PubMed, National Library of Medicine. Key words included COVID-19, SARS-CoV-2, AAA, ACE2, ACE or angiotensin II type 1 (AT1) receptor inhibitor, angiotensin 1-7, Mas receptor, age, gender, respiratory diseases, diabetes, and autoimmune diseases. Key publications on the epidemiology and pathogenesis of COVID-19 and AAAs were identified and reviewed. RESULTS: All vascular structural cells, including endothelial and smooth muscle cells, fibroblasts, and pericytes express ACE2. Cigarette smoking, diabetes, chronic obstructive pulmonary disease, lupus, certain types of malignancies, and viral infection promote ACE2 expression and activity, with the magnitude of response varying by sex and age. Genetic deficiency of AT1 receptor, or pharmacologic ACE or AT1 inhibition also increases ACE2 and its catalytic product angiotensin 1-7. Genetic ablation or pharmacologic inhibition of ACE2 or Mas receptor augments, whereas ACE2 activation or angiotensin 1-7 treatment attenuates, progression of experimental AAAs. The potential influences of SARS-CoV-2 on AAA pathogenesis include augmented ACE-angiotensin II-AT1 receptor activity resulting from decreased reciprocal ACE2-angiotensin 1-7-Mas activation; increased production of proaneurysmal mediators stimulated by viral spike proteins in ACE2-negative myeloid cells or by ACE2-expressing vascular structural cells; augmented local or systemic cross-talk between viral targeted nonvascular, nonleukocytic ACE2-expressing cells via ligand recognition of their cognate leukocyte receptors; and hypoxemia and increased systemic inflammatory tone experienced during severe COVID-19 illness. CONCLUSIONS: COVID-19 may theoretically influence AAA disease through multiple SARS-CoV-2-induced mechanisms. Further investigation and clinical follow-up will be necessary to determine whether and to what extent the COVID-19 pandemic will influence the prevalence, progression, and lethality of AAA disease in the coming decade.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Xu B, Li G, Guo J, et al. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms. J Vasc Surg. 2021. PMID: 33600934. doi:10.1016/j.jvs.2021.01.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。